Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000728644 | SCV000856244 | uncertain significance | not provided | 2017-08-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000728644 | SCV002360970 | likely benign | not provided | 2025-01-01 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000728644 | SCV002541822 | uncertain significance | not provided | 2021-07-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003165959 | SCV003912009 | uncertain significance | Cardiovascular phenotype | 2023-02-28 | criteria provided, single submitter | clinical testing | The c.694+5G>C intronic variant results from a G to C substitution 5 nucleotides after coding exon 5 in the ABCG8 gene. This alteration has been reported in dyslipidemia cohorts (Yang Y et al. Curr Pharm Des, 2019;25:190-200; Kojima N et al. Clin Chim Acta, 2020 Aug;507:11-16; Hu X et al. Gene, 2021 Feb;768:145310). This alteration has also been reported in a sitosterolemia cohort (Xia Y et al. J Clin Lipidol, 2022 Dec;16:40-51). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration may weaken the native splice donor site. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |